Get started
SPDR S&P BIOTECH ETFSPDR S&P BIOTECH ETFSPDR S&P BIOTECH ETF

SPDR S&P BIOTECH ETF

No trades
See on Supercharts
OverviewChartAnalysisHoldingsNewsIdeasDiscussionsSeasonals

SSGF chart



Key stats


Assets under management (AUM)
‪4.71 B‬ EUR
Fund flows (1Y)
—
Dividend yield (indicated)
0.04%
Discount/Premium to NAV
—
Shares outstanding
‪49.14 M‬
Expense ratio
0.35%

About SPDR S&P BIOTECH ETF


Issuer
State Street Corporation
Brand
SPDR
Home page
us.spdrs.com
Inception date
Jan 31, 2006
Structure
Open-Ended Fund
Index tracked
S&P Biotechnology Select Industry
Replication method
Physical
Management style
Passive
Dividend treatment
Distributes
Distribution tax treatment
Qualified dividends
Income tax type
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Primary advisor
SSgA Funds Management, Inc.
Distributor
State Street Corp. (Fund Distributor)
ISIN
US78464A8707
XBI provides exposure to US biotech stocks, as defined by GICS, from a universe that invests across the market-cap spectrum. The fund equal-weights its portfolio, which in turn emphasizes small- and micro-caps and greatly reduces single-name risk. Thus, the weighted-average market-cap is much smaller than some competitors. Unlike other funds in this segment, XBI is a pure biotech play, with relatively small pharma overlap. The index is rebalanced quarterly.

Broaden your horizons with more funds linked to SSGF via country, focus, and more.

Classification


Asset Class
Equity
Category
Sector
Focus
Health care
Niche
Biotechnology
Strategy
Equal
Geography
U.S.
Weighting scheme
Equal
Selection criteria
Market cap

SSGF analysis


What's in the fund
Exposure type
StocksBonds, Cash & Other
Health Technology
Stock breakdown by region
93%6%
Top 10 holdings

SSGF news



Ideas



See all ideas 

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


An exchange-traded fund (ETF) is a collection of assets (stocks, bonds, commodities, etc.) that track an underlying index and can be bought on an exchange like individual stocks.
SSGF assets under management is ‪4.71 B‬ EUR. AUM is an important metric as it reflects the fund's size and can serve as a gauge of how successful the fund is in attracting investors, which, in its turn, can influence decision-making.
Since ETFs work like an individual stock, they can be bought and sold on exchanges (e.g. NASDAQ, NYSE, EURONEXT). As it happens with stocks, you need to select a brokerage to access trading. Explore our list of available brokers to find the one to help execute your strategies. Don't forget to do your research before getting to trading. Explore ETFs metrics in our ETF screener to find a reliable opportunity.
SSGF invests in stocks. See more details in our Analysis section.
SSGF expense ratio is 0.35%. It's an important metric for helping traders understand the fund's operating costs relative to assets and how expensive it would be to hold the fund.
No, SSGF isn't leveraged, meaning it doesn't use borrowings or financial derivatives to magnify the performance of the underlying assets or index it follows.
Yes, SSGF pays dividends to its holders with the dividend yield of 0.04%.
SSGF shares are issued by State Street Corp.
SSGF follows the S&P Biotechnology Select Industry. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
The fund started trading on Jan 31, 2006.
The fund's management style is passive, meaning it's aiming to replicate the performance of the underlying index by holding assets in the same proportions as the index. The goal is to match the index's returns.